The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
HOME > BUSINESS
BUSINESS
- Sumitomo Dainippon Beats 1st Half Guidance, Ups Full-Year Outlook
October 31, 2017
- Shionogi Notches Double-Digit Sales Rise on HIV/Flu Royalties
October 31, 2017
- JT, Torii to Jointly Develop HIF-PH inhibitor in Japan
October 30, 2017
- JCR Starts Development of Another BBB-Penetrating Drug for Hurler Syndrome
October 30, 2017
- Mogamulizumab Accepted for Review in Europe: Kyowa Kirin
October 30, 2017
- JSR Grabs License to Gut Bacteria Research Outcome by Keio Univ./Univ. of Tokyo, I/O Drug Discovery Eyed
October 30, 2017
- Crestor Generics of Sawai, Pfizer to Get Listed with Full Indications
October 27, 2017
- Eisai Ups Profit Estimates for April-September
October 27, 2017
- Ono Lifts Half-Year Guidance on Opdivo Boon
October 27, 2017
- Mitsubishi Tanabe Withdraws Petitions for Injunction against 3 Generic Makers Over Talion Patent Infringement
October 27, 2017
- Fujifilm Invests in Japan Biomedical to Boost Regenerative Medicine Business
October 27, 2017
- Novartis Seeks SJIA Indication for Ilaris in Japan
October 26, 2017
- Shionogi’s Sakigake-Designated Flu Med Filed in Japan
October 26, 2017
- Parmodia, Canalia Climb GP Recollection Ranking in August: Anterio
October 25, 2017
- Sumitomo Dainippon Joins Forces with Nobel Laureate to Tackle AMR Infections
October 25, 2017
- Expanded Aducanumab Collaboration Will Be a Plus for Other Alzheimer’s Pipelines: Eisai CEO
October 25, 2017
- Mitsubishi Tanabe Trims Forecast on Sluggish Invokana Royalties
October 25, 2017
- BMS, Pfizer Launch Japan Clinical Research for Atrial Fibrillation Detection
October 24, 2017
- Eisai Opts to Codevelop Biogen’s Aducanumab; New MS Copromotion Scheme Sealed
October 24, 2017
- Shionogi Ups Earnings Outlook on Milestone Scheme Change
October 24, 2017
ページ
The pharmaceutical industry is ever-changing. Recruiters must evolve accordingly and prepare well in advance for future talent needs.This means predicting the changes and trends that will impact the market, industry, and your organization, and how this will affect talent requirements.…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…